Treatment of Urticaria Pigmentosa with Corticosteroids

John Barton, Robert M. Lavker, Norman M. Schechter, Gerald Sylvan Lazarus

Research output: Contribution to journalArticle

Abstract

Based on a previous observation that the long-term application of potent topical corticosteroids under occlusion to normal skin resulted in the loss of mast cells, we investigated the effects of intralesional and topical steroids in urticaria pigmentosa (UP). Three patients with UP had lesions that were injected with triamcinolone acetonide. Four weeks after injection, all patients showed a loss of Darier's sign, and, by eight weeks after injection, there was a dramatic clearing of the plaques and a decrease in brown hyperpigmentation. By 12 weeks, mast cells were undetectable by light microscopy and transmission electron microscopy (TEM). The injection sites remained dramatically improved for as long as one year after treatment, and histamine content was reduced 95% in one patient 48 weeks after injection. In six patients, the topical application of 0.05% betamethasone dipropionate under occlusion to limited areas induced almost complete clearing of UP lesions. Lesions treated with an emollient under occlusion, as a control, demonstrated no change. After treatment, no mast cells were seen by light microscopy or TEM, and this persisted for at least 24 weeks. There was also a significant decrease in tissue histamine levels in the treated areas. The treated areas remained clinically improved for at least nine to 12 months. These data indicate that steroid therapy dramatically decreases the excess number of normal-appearing mast cells in UP as well as induces a prolonged resolution of UP lesions. Local corticosteroids thus are a useful therapeutic modality for UP.

Original languageEnglish (US)
Pages (from-to)1516-1523
Number of pages8
JournalArchives of Dermatology
Volume121
Issue number12
DOIs
StatePublished - 1985
Externally publishedYes

Fingerprint

Urticaria Pigmentosa
Adrenal Cortex Hormones
Mast Cells
Injections
Transmission Electron Microscopy
Histamine
Microscopy
Therapeutics
Steroids
Emollients
Light
Triamcinolone Acetonide
Hyperpigmentation
Observation
Skin

ASJC Scopus subject areas

  • Dermatology

Cite this

Treatment of Urticaria Pigmentosa with Corticosteroids. / Barton, John; Lavker, Robert M.; Schechter, Norman M.; Lazarus, Gerald Sylvan.

In: Archives of Dermatology, Vol. 121, No. 12, 1985, p. 1516-1523.

Research output: Contribution to journalArticle

Barton, John ; Lavker, Robert M. ; Schechter, Norman M. ; Lazarus, Gerald Sylvan. / Treatment of Urticaria Pigmentosa with Corticosteroids. In: Archives of Dermatology. 1985 ; Vol. 121, No. 12. pp. 1516-1523.
@article{0bfaaa3e68234dbaa48c02d1c6534f75,
title = "Treatment of Urticaria Pigmentosa with Corticosteroids",
abstract = "Based on a previous observation that the long-term application of potent topical corticosteroids under occlusion to normal skin resulted in the loss of mast cells, we investigated the effects of intralesional and topical steroids in urticaria pigmentosa (UP). Three patients with UP had lesions that were injected with triamcinolone acetonide. Four weeks after injection, all patients showed a loss of Darier's sign, and, by eight weeks after injection, there was a dramatic clearing of the plaques and a decrease in brown hyperpigmentation. By 12 weeks, mast cells were undetectable by light microscopy and transmission electron microscopy (TEM). The injection sites remained dramatically improved for as long as one year after treatment, and histamine content was reduced 95{\%} in one patient 48 weeks after injection. In six patients, the topical application of 0.05{\%} betamethasone dipropionate under occlusion to limited areas induced almost complete clearing of UP lesions. Lesions treated with an emollient under occlusion, as a control, demonstrated no change. After treatment, no mast cells were seen by light microscopy or TEM, and this persisted for at least 24 weeks. There was also a significant decrease in tissue histamine levels in the treated areas. The treated areas remained clinically improved for at least nine to 12 months. These data indicate that steroid therapy dramatically decreases the excess number of normal-appearing mast cells in UP as well as induces a prolonged resolution of UP lesions. Local corticosteroids thus are a useful therapeutic modality for UP.",
author = "John Barton and Lavker, {Robert M.} and Schechter, {Norman M.} and Lazarus, {Gerald Sylvan}",
year = "1985",
doi = "10.1001/archderm.1985.01660120042017",
language = "English (US)",
volume = "121",
pages = "1516--1523",
journal = "JAMA Dermatology",
issn = "2168-6068",
publisher = "American Medical Association",
number = "12",

}

TY - JOUR

T1 - Treatment of Urticaria Pigmentosa with Corticosteroids

AU - Barton, John

AU - Lavker, Robert M.

AU - Schechter, Norman M.

AU - Lazarus, Gerald Sylvan

PY - 1985

Y1 - 1985

N2 - Based on a previous observation that the long-term application of potent topical corticosteroids under occlusion to normal skin resulted in the loss of mast cells, we investigated the effects of intralesional and topical steroids in urticaria pigmentosa (UP). Three patients with UP had lesions that were injected with triamcinolone acetonide. Four weeks after injection, all patients showed a loss of Darier's sign, and, by eight weeks after injection, there was a dramatic clearing of the plaques and a decrease in brown hyperpigmentation. By 12 weeks, mast cells were undetectable by light microscopy and transmission electron microscopy (TEM). The injection sites remained dramatically improved for as long as one year after treatment, and histamine content was reduced 95% in one patient 48 weeks after injection. In six patients, the topical application of 0.05% betamethasone dipropionate under occlusion to limited areas induced almost complete clearing of UP lesions. Lesions treated with an emollient under occlusion, as a control, demonstrated no change. After treatment, no mast cells were seen by light microscopy or TEM, and this persisted for at least 24 weeks. There was also a significant decrease in tissue histamine levels in the treated areas. The treated areas remained clinically improved for at least nine to 12 months. These data indicate that steroid therapy dramatically decreases the excess number of normal-appearing mast cells in UP as well as induces a prolonged resolution of UP lesions. Local corticosteroids thus are a useful therapeutic modality for UP.

AB - Based on a previous observation that the long-term application of potent topical corticosteroids under occlusion to normal skin resulted in the loss of mast cells, we investigated the effects of intralesional and topical steroids in urticaria pigmentosa (UP). Three patients with UP had lesions that were injected with triamcinolone acetonide. Four weeks after injection, all patients showed a loss of Darier's sign, and, by eight weeks after injection, there was a dramatic clearing of the plaques and a decrease in brown hyperpigmentation. By 12 weeks, mast cells were undetectable by light microscopy and transmission electron microscopy (TEM). The injection sites remained dramatically improved for as long as one year after treatment, and histamine content was reduced 95% in one patient 48 weeks after injection. In six patients, the topical application of 0.05% betamethasone dipropionate under occlusion to limited areas induced almost complete clearing of UP lesions. Lesions treated with an emollient under occlusion, as a control, demonstrated no change. After treatment, no mast cells were seen by light microscopy or TEM, and this persisted for at least 24 weeks. There was also a significant decrease in tissue histamine levels in the treated areas. The treated areas remained clinically improved for at least nine to 12 months. These data indicate that steroid therapy dramatically decreases the excess number of normal-appearing mast cells in UP as well as induces a prolonged resolution of UP lesions. Local corticosteroids thus are a useful therapeutic modality for UP.

UR - http://www.scopus.com/inward/record.url?scp=0022343136&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022343136&partnerID=8YFLogxK

U2 - 10.1001/archderm.1985.01660120042017

DO - 10.1001/archderm.1985.01660120042017

M3 - Article

C2 - 4062333

AN - SCOPUS:0022343136

VL - 121

SP - 1516

EP - 1523

JO - JAMA Dermatology

JF - JAMA Dermatology

SN - 2168-6068

IS - 12

ER -